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Abstract 
Background: Few studies have investigated metabolic complications in HIV-infected African 
children and their relation with inflammation. 
Methods: We compared baseline and changes in insulin resistance (HOMA-IR) and in markers 
of inflammation over 48 weeks, in a subset of antiretroviral therapy (ART) naïve Ugandan 
children from the CHAPAS-3 trial randomized to zidovudine (AZT), stavudine (D4T) or 
abacavir (ABC) based regimens.  Non-parametric methods were used to explore between and 
within group differences and multivariable analyses to assess associations of HOMA-IR. 
Results: 118 children were enrolled; median age (IQR) was 2.8 years (1.7-4.3).  Baseline median 
HOMA-IR (IQR) was 0.49 (0.38, 1.07) and similar between the arms.  At week 48, median 
relative changes in HOMA-IR were 14% (-29%, 97%) in the AZT arm, -1% (-30%, 69%) in the 
D4T arm, and 6% (-34%, 124%) in the ABC arm (p≤0.03 for all arms compared to baseline, but 
p=0.90 for between-group differences). Several inflammation markers significantly decreased in 
all study arms; sCD14 increased on ABC and did not change in the other two arms. In 
multivariate analysis, only changes in sCD163 were positively associated with HOMA-IR 
changes.  
Conclusions: In ART naïve Ugandan children, HOMA-IR changed significantly after 48 weeks 
of ART and correlated with monocyte activation. 
Key words: insulin resistance, pediatric HIV, Uganda, treatment –naïve, inflammatory markers, 
monocyte activation 
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Cardiovascular and metabolic diseases have become the leading cause of death in HIV-
infected individuals
2
 and specifically disorders of glucose metabolism and insulin resistance 
have increasingly been reported in HIV-infected patients
3-7
.  HIV-infected children also have a 
higher prevalence of metabolic disorders compared to the general population
8-10
. Limited 
longitudinal data also indicate an increased prevalence of insulin resistance in HIV-infected 
children over time
11,12
.  Persistent insulin resistance may increase the lifetime risk of developing 
type 2 diabetes mellitus
13
. The etiology is likely multifactorial including HIV
18
, specific 
antiretroviral regimen (ART)
19,20
 and systemic inflammation
4
. 
 Markers of systemic inflammation have been associated with the development of 
diabetes and cardiovascular disease in the general population
21-23
.  Although ART decreases 
inflammation and coagulation markers
31,32
 levels of inflammatory markers may remain elevated 
despite virologic suppression. In HIV-infected individuals on ART with good HIV virologic 
control, markers of systemic inflammation remain higher than in HIV-uninfected individuals
33
.   
The available limited research evaluating the impact of inflammation in virally 
suppressed patients has been focused in resource-rich settings and it remains unclear how this 
relates to pediatric patients in resource-limited settings where the majority of pediatric HIV-
infected patients live.  Participants from the Children with HIV in Africa-Pharmacokinetics and 
Adherence/Acceptability of Simple Antiretroviral Regimens (CHAPAS-3) trial who enrolled in 
Kampala at the Joint Clinical Research Centre (JCRC) present a unique opportunity to examine 
changes in insulin resistance after ART initation. 
METHODS 
This was a sub study of the CHAPAS 3 clinical trial (ISRCTN69078957), which was an open 
randomized phase II/III trial comparing toxicity and efficacy of stavudine (D4T)-, zidovudine 
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(AZT) - and abacavir (ABC)-based ART among children from Zambia and Uganda
17
. There 
were four participating sites: University Teaching Hospital, Lusaka, Zambia and Baylor-Uganda 
Centre of Excellence, Kampala; Joint Clinical Research Centre (JCRC), Kampala and JCRC, 
Gulu, in Uganda. Caregivers gave written informed consent; older children aware of their HIV 
status also gave informed assent following national guidelines. The trial was approved by 
Research Ethics Committees (REC) in Zambia, Uganda and UK. The sub study protocol was 
also approved by the JCRC REC and the Uganda National Council of Science and Technology.   
 The primary objectives of CHAPAS 3 were to determine toxicity and pharmacokinetics 
of the 3 treatment regimens in the pediatric population {Mulenga, 2016 #147}.  The sub study 
presented in this paper focused on the 119 ART naïve children aged 3 months to 4 years that 
were recruited at JCRC, Kampala. 
Study Evaluations 
At entry and week 48, fasting (6 hours) blood was obtained for real time measurements of lipid 
profiles and CD4 count.  Blood was processed and plasma stored for batched measurement of 
HIV-RNA levels.  A Material Transfer Agreement, approval from the Uganda National Council 
of Science and Technology as well as a permit from the Center for Disease Control were 
approved after which the remainder of the frozen, never previously thawed plasma from the ART 
naïve children was shipped to Case Medical Center, Cleveland, USA.  The plasma samples were 
used for measurement of glucose, insulin, soluble and cellular markers of monocyte immune 
activation and markers of systemic inflammation and coagulation. Measurements were 
performed by the Dahms Research Clinical Unit which is part of the Case Clinical and 
Translational Science Collaborative of Cleveland (CTSC).  Insulin was measured by ELISA 
sandwich immunoassay (ALPCO, Salem, New Hampshire, USA) and the derived homeostatic 
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model assessment of insulin resistance (HOMA-IR) was calculated as described
34
, where insulin 
resistance is defined categorically as levels of HOMA-IR greater than 3.16
34,35
 
Inflammation, coagulation and soluble immune activation markers 
Plasma markers of monocyte activation (sCD14 and sCD163), systemic inflammation (sTNFR1 
and 2), oxidized LDL, and fibrinogen were measured.  All markers were measured by ELISA (R 
& D Systems, Minneapolis, Minnesota, USA and ALPCO, Salem, New Hampshire, USA).   
Statistical analysis 
The primary objective of this analysis was to determine changes in HOMA-IR and markers of 
inflammation 48 weeks after initiating the randomized treatments and to compare the changes 
between the groups.   Secondary objectives were to determine the association between HOMA-
IR and markers of systemic inflammation at baseline with clinically relevant factors and to 
explore predictors of change in HOMA-IR and changes in markers. 
Weight- and height-for-age Z scores were obtained from WHO growth chart standards.  Baseline 
demographics, HIV-related factors, metabolic risk factors and HOMA-IR were described overall 
and by randomization group using median and interquartile range (IQR) for continuous variables 
and frequency and percent for categorical variables. Absolute and relative changes from baseline 
to week 48 were determined. To highlight the magnitude of the observed difference in HOMA-
IR after ART initiation.  Baseline variables, as well as absolute and relative changes, were 
compared in the 3 groups with the Kruskal-Wallis test for continuous variables and by the chi-
square test or Fisher’s exact test, as appropriate for categorical variables. Within group changes 
were tested using the Wilcoxon matched pairs signed ranks test and Spearman correlations were 
used to assess associations with HOMA-IR.   
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Multivariable linear regression was used to model the relative change in HOMA-IR over 48 
weeks, with variables with p<0.1 in the correlation analysis as well as variables known to affect 
insulin resistance including age, sex, BMI and family history of diabetes, being candidates for 
inclusion in the model. Mathematical transformations were used to achieve normality of 
distribution, as needed. The variance inflation factor (VIF) statistic was used to gauge possible 
collinearity.  Possible departures from normality of residuals and homoescedasticity were 
evaluated using graphical methods. All analyses were initially performed including all 
participants and all available data.  The results of the analyses including all participants did not 
differ from the sensitivity analyses performed including only participants with undetectable viral 
load at week 48; therefore only the former data are presented. 
Analyses were performed with SAS9.4 (SAS Institute, Cary, NC). 
RESULTS 
Baseline Characteristics 
Overall, 118 out of 119 ART naïve CHAPAS 3 participants at JCRC, Kampala had stored 
plasma samples available for HOMA-IR and inflammatory markers measurements and were 
included in the present analysis.  Demographic information and baseline characteristics of the 
118 participants are displayed in Table 1; except for viral load which was higher in the D4T arm 
compared to the ABC arm, all other indices were similar between groups (p>0.05).  Median age 
(Q1, Q3) was 2.8 (1.5, 4.3) years; 49% were male.  Median weight-for-age Z score was -2 (-3.4, 
-0.5) and HOMA-IR was 0.49 (0.38, 1.07).  A total of 5 participants had HOMA-IR values ≥ 
3.16.  Median absolute and percent CD4+ T cell counts were 867 (648, 1544) cells/mm
3
 and 
20% (15, 25) respectively.  Median viral load was 405,755 (122,250, 1,107,900) copies/mL.  
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Levels of markers of systemic inflammation and monocyte activation were also similar between 
groups. 
Changes in HOMA-IR after ART Initiation 
The relative changes from baseline to week 48 in HOMA-IR are shown in Figure 1.  The relative 
changes in HOMA-IR did not differ between arms, and were a median (Q1, Q3) of 14% (-29%, 
97%) in the AZT arm (p=0.03); -1% (-30%, 69%) in the D4T arm (p=0.02); and 6% (-34%, 
124%) in the ABC arm (p=0.02).  Four additional participants had HOMA-IR values ≥ 3.16 
compared to baseline, with no differences between the arms.  Within-group percentage changes 
in HOMA-IR were different from the absolute changes (see Table 2).  The absolute changes in 
HOMA-IR were not significant in any of the arms.   
Changes in Inflammatory Biomarkers after ART Initiation 
sTNFR1 and 2, and sCD163 all decreased significantly (p<0.05 compared to baseline) within 
each of the three groups.  sTNFR1 decreased by a median (Q1,Q3) 18% (9, 27%) in the AZT 
arm (p=<0.001), 19% (4, 32%) in the D4T arm  (p=0.05) and 18% (3, 30%) in the ABC arm 
(p<0.001); sTNFR2 decreased by 39% (32, 53%) in the AZT arm (p<0.0001), 32% (30, 56%) in 
the D4T arm (P<0.0001), 41% (23, 58%) in the ABC arm (p<0.0001); sCD163 decreased by 
31% (23%, 47%) in the AZT arm (p<0.0001), 27% (2, 40%) in the D4T arm (p<0.0001) and 
20% (7, 45%) in the ABC arm (p=0.02). The changes were not significantly different between 
groups (p≥0.09).  sCD14 did not change in the AZT or D4T arms with median changes of 5% (-
12, 19%) in the AZT arm (p=0.14) and median decrease of 0.4% (14, 19%) in the D4T arm 
(p=0.12).  sCD14 increased significantly in the ABC arm by a median of 16% (-0.09%, 33%, 
p=0.0003).  There was no difference in sCD14 between the AZT and D4T arms (p=0.72); 
however the changes in sCD14 were significantly different between AZT, D4T and the ABC arm 
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(p<0.05).  Oxidized LDL and fibrinogen did not change significantly within any of the groups 
and did not differ between groups (p≥0.2).  Within-group percentage changes in levels of the 
inflammatory biomarkers were similar to the absolute changes (Figure 1 and Table 2).   
Changes in Other Clinically Relevant Factors after ART Initation 
There were significant increases in weight and height in all arms with absolute median changes 
of weight-for-age Z score of  0.7 (IQR, 0.02, 1.72, p<0.01 for all arms); and absolute changes of 
height-for-age Z score of 0.4 (-0.03, 0.94, p<0.01 for all arms).  The absolute median change in 
BMI significantly increased in the AZT arm (p=0.02) but not in the D4T or ABC arms (p≥0.44).  
Total cholesterol, HDL and LDL increased within each of the arms (p≤0.03).  
After 48 weeks of ART,  66% of patients had undetectable viral load in the AZT arm, 57% in the 
D4T arm and 63% in the ABC arm; CD4 percent increased significantly in all arms with absolute 
median increase of 14% (IQR, 8.5, 19.5, p<0.01) for all arms. Insulin did not change at week 48 
in any of the arms (p>0.05).  Except for median glucose that increased significantly only in the 
AZT arm [62 mg/dL (IQR, 50, 72) at baseline; 69 mg/dL (58, 80); p=0.03) at week 48], there 
were no significant changes between the arms for any of the other clinically relevant factors. 
Baseline associations with HOMA-IR and inflammatory markers 
At baseline (pre-ART), the only inflammatory marker associated with HOMA-IR was oxidized 
LDL (α=-0.20, p=0.04).  Oxidized LDL was also negatively associated with weight and 
positively associated CD4 count.  Soluble TNF alpha receptors I and II and sCD14 were 
negatively associated with weight, age and weight-for-age Z score as well as total and LDL 
cholesterol.  sTNFR1 and 2 were positively associated with absolute CD4 count and viral load, 
whereas sCD14 was only negatively associated with %CD4 (table 3).   
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Associations between Changes in HOMA-IR and Changes in Biomarkers  
Changes in sCD163 levels were positively associated with changes in HOMA-IR (see table 4).  
After adjusting for parameters known to affect insulin resistance including age, sex, BMI and 
family history of diabetes, only changes in sCD163 remained independently associated with 
changes in HOMA-IR (β coefficient= 0.635, p=0.03).   
After 48 weeks of ART, changes in %CD4 count, in weight and LDL cholesterol were 
negatively associated with changes in sTNFR1 and 2, and in sCD14 (p< 0.05).  After adjusting 
for age, sex and LDL, increase in weight remained independently associated with reductions in 
sTNFR1 and 2(β coefficient= -0.62, p<0.01 and β coefficient= -0.42, p=0.05 respectively).  
Weight also remained independently associated with sCD14 after adjusting for age, sex, viral 
load and CD4 (β coefficient= -0.63, p=0.02). All VIFs were <2.0. 
DISCUSSION 
We investigated the effects of 48 weeks of ART in treatment naïve Ugandan children on 
insulin resistance and markers of inflammation.  Data are lacking on the effects of ART on 
metabolic and inflammatory parameters in African children where the bulk of HIV-infected 
children reside.  We found that in the setting of an NNRTI-based regimen, zidovudine and 
abacavir increased HOMA-IR and that HOMA-IR is associated with the marker of monocyte 
activation sCD163.   
Insulin resistance is a state in which insulin is associated with an abnormal glucose response 
and correlates with sequelae such as the development of diabetes
13
, cardiovascular disease and 
malignancies.  Although there are no reference values for HOMA-IR in healthy Ugandan 
children, the baseline HOMA-IR values in our population of underweight HIV-positive Ugandan 
children were similar to those reported in normal weight HIV-negative European children of 
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similar age
36
 and below 3.16 which has been defined as the cut off for defining insulin resistance 
in children 
35
.  The clinical significance of the increase seen in HOMA-IR in the zidovudine and 
abacavir arms after only 48 weeks is unclear.  In addition, it is unknown whether this increase in 
insulin resistance would translate to important long term consequences in this prepubertal cohort.  
Other studies have also demonstrated increased insulin resistance in HIV-infected children
9,11,37
.  
In the study by Chantry et al, participants were either initiating or switching ART regimen
11
.  In 
this particular study, 25% of their patients were three years of age and under, the baseline 
HOMA-IR value was 0.8  which is similar to our study; however the change seen after 48 weeks 
was between 0.2-0.8, comparatively larger than the absolute change in our study of -0.01-0.04.   
However, unlike the participants in our study, these children were on protease inhibitor based 
therapy  which has been linked to insulin resistance in HIV-infected adults
38
 and children
39
.  
Median HOMA-IR values reported by Innes et al in a cross sectional study of HIV-infected 
children in South Africa were also 0.8 but not different between children on lopinavir and 
efavirenz based regimens. 
 A novel finding is the relationship between HOMA-IR and the marker of monocyte 
activation sCD163 in HIV-infected children.  Soluble CD163 has been associated with HOMA-
IR in healthy adults and obese children
22,40,41
 but to our knowledge no similar correlation has 
been reported in HIV-infected subjects.  sCD163 in HIV-infected adults has been linked with 
other prevalent and clinically significant co-morbidities in HIV-infection including noncalcified 
plaque 
42
 and neurocognitive impairment
43
.  Unlike what we have found in our previous study in 
HIV-infected adults, sTNFα receptors were not significantly correlated with insulin resistance4. 
We may not have been able to detect an association secondary to the small sample size of our 
study.  Another hypothesis that has been proposed by Zanni et al
22, is that TNFα, because of its 
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short half-life, may not reflect the inflammation in adipose tissues, unlike CD163 expressing 
macrophages which can gain access to fat cells.  Microbial translocation and lipopolysaccharides 
may play a role in the correlation seen between sCD163 and insulin resistance.  Microbial 
translocation has been well documented in HIV-infected adults
44
 and more recently in ART-
naïve children in resource limited settings
45
.  Markers of microbial translocation have been 
closely associated with several cardiovascular risk factors including insulin resistance
46,47
 and are 
potent stimulants for release of sCD163 from adipose tissue 
48
.  We found that after controlling 
for known demographic characteristics the relationship between sCD163 and HOMA-IR 
remained statistically significant.  These findings suggest that insulin resistance in HIV-infected 
children may be mediated by immune activation particularly monocyte activation. 
Several markers of inflammation (sTNFR1 and 2 and sCD163) decreased significantly after 
48 weeks of ART; however, sCD14 did not decrease, and even increased in the ABC arm despite 
virologic suppression.  In addition, oxidized LDL did not significantly change after 48 weeks of 
ART.  Oxidized LDL is a marker of oxidative stress and in adults in uninfected adults has been 
associated with obesity
27
, insulin resistance
28
 and cardiovascular disease
29
 and in HIV has been 
associated with markers of immune activation
30
.  The lack of change seen in oxidized LDL after 
48 weeks of ART may be linked to the lack of change seen in sCD14 as our group has previously 
shown that plasma levels of oxidized LDL and sCD14 in HIV-infected patients are closely 
related and oxidized LDL may play a role in monocyte activation
49
. 
sCD14 contributes to the long term complications seen in HIV and has been linked to 
subclinical atherosclerosis
50
 and overall mortality in HIV
24
. One possible explanation is that 
Ugandan children are exposed to different pathogens that could impact their intestinal 
microbiome. In addition, NNRTI-based regimens may not fully suppress viral replication in the 
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gastrointestinal tract in order to control bacterial translocation. However, similar findings were 
seen in HIV-infected youth from the United States who were initiated on a protease inhibitor 
based regimen with tenofovir and lamivudine
51
.  In this study, higher levels of sCD14 compared 
to baseline levels persisted despite 48 weeks of ART and viral suppression.   Our group has 
previously reported on ART-naïve adults randomized to different ART regimens and found that 
sCD14 decreased only in the integrase inhibitor arms but not with protease inhibitor or NNRTI 
based regimens
50,52,53
.  One of the mechanisms hypothesized is a higher concentration of 
integrase inhibitor in the enterocytes leading to better control over bacterial translocation
52
.  
These data suggest HIV-infected Ugandan children even at a young age have increased immune 
activation and possibly bacterial translocation as measured by sCD14 that do not improve with 
early viral suppression with NNRTI based regimens. 
From a metabolic standpoint, we found that cholesterol, HDL and LDL increased in all arms.  
Unlike what was seen in ART naïve Ugandan children of similar age enrolled in the ARROW 
trial, total and HDL cholesterol were not lower in the AZT arm compared to the other two 
arms
54
.  After adjusting for parameters known to affect inflammatory markers, an increase in 
weight remained associated with reductions in sTNFR1 and 2 and sCD14.  This is consistent 
with data recently presented in HIV-infected adults  from the Propsective Evaluation of 
Antiretrovirals in Resource Limited Settings (PEARLS) trial that found that among HIV-infected 
persons initiating ART in resource-diverse settings, weight gain among underweight persons had 
a trend towards lower levels of TNFα- and sCD14 whereas weight gain among obese persons 
was found to heighten inflammation/immune activation
55
.  Our findings suggest that ART 
initiation among HIV-infected children in resource limited settings, weight gain may reduce 
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systemic inflammation and immune activation. Another possibility is that inflammation is 
reduced due to better virologic control and the weight increase is a reflection of return to health.  
Strengths of our study include randomized treatment allocation and evaluation of metabolic 
and inflammatory parameters in a young Ugandan cohort before and after ART initiation.  We 
did not have a comparison group of HIV uninfected children to compare the natural changes seen 
in insulin resistance in Ugandan children.  In addition, we cannot prove causal relationships or 
exclude the possibility of residual confounding.  We focused on a specific population of young 
HIV-infected Ugandan children whom were underweight at baseline, therefore our findings may 
not be applicable to other HIV-infected populations.  
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Figure 1 Relative change in HOMA-IR and inflammatory markers 
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Table 1: Baseline demographic, Clinical, HIV related factors and Inflammatory Biomarkers by 
Arms 
 AZT arm 
N=35 
D4T arm 
N=42 
ABC arm 
N=41 
Age (years) 3.3 (1.7, 4.3) 2.9 (1.8, 3.9) 2.3 (1.5, 3.9) 
Male sex 18 (51%) 19(45%) 21(51%) 
Weight, kg 10 (8, 14) 11.7 (9, 14) 11 (8, 13) 
Height, cm 82 (73.2, 93.6) 85.8 (76.0, 95.4) 80 (72.5, 92.4) 
BMI (kg/m
2
) 15.6(14.50, 16.53) 15.08(14.46, 
17.04) 
16.04(15.56,16.7
9) 
Weight-for-age Z score -2 (-3.4, -1.0) -1.8 (-3.2, -0.7) -2.1 (-2.6, -0.5) 
Height-for-age Z score -2.4 (-3.5,-1.1) -2.6 (-3.3, -1.3) -2.4 (-3.6, -1.4) 
Family History of Diabetes 3 (9%) 3 (7%) 2 (5%) 
Glucose level (mg/dL) 62 (50, 72) 63.3 (57, 68) 59.5 (53, 69) 
Insulin (uIU/mL) 3 (3, 3.2) 3 (3, 3) 3 (3, 6.8) 
HOMA-IR  0.48 (0.38, 0.57) 0.49 (0.43, 0.57) 0.49 (0.41, 1.07) 
HOMA-IR ≥3.16 1 (3%) 2(5%) 2 (5%) 
Total Cholesterol level, mg/dL 116.6 (99.8, 140.5) 116 (99.4, 146.0) 128.1 (97.7, 
152.4) 
High-density lipoprotein 
(mg/dL) 
26.3 (18.2, 30.1) 25.9 (19.1, 32.4) 24 (19.8, 34.2) 
Low-density lipoprotein 
(mg/dL) 
66 (42.5, 85.8) 66.9 (48.4, 87.7) 67.2 (50.7, 95.5) 
Triglycerides (mg/dL) 111 (87.6, 159.9) 102.6 (83.6, 
177.2) 
114.5 (89.7, 
144.1) 
Viral load (copies/mL) 401,200 (171,650, 
1,079,645) 
500,975 (224,805, 
1,107,900)
 a
 
315,090 
(122,250, 
646,190)
 a
 
CD4+ T cell counts (cells/mm
3
) 925.5 (676, 1505) 864.7 (648, 1236) 810.5 (672, 
1544) 
CD4+ T cell percent 21 (16, 25) 19.5 (15, 22) 21 (16.5, 24) 
sTNFR1 (pg/mL) 1221 (926, 1429) 1249 (993, 1480) 1188 (995, 
1572) 
sTNFR2 (pg/mL) 5739.5 (4848, 7263) 5851 (4210, 7272) 5478 (4482, 
8805) 
sCD14 (ng/mL) 1750.5 (1394, 2260) 1778.8 (1578, 
2298) 
2007.5 (1615, 
2308) 
sCD163 (ng/mL) 1417.5 (1154, 1588) 1345 (1118, 1533) 1340.3 (970, 
1680) 
Oxidized LDL (u/L) 140 (64, 263) 122.5 (62, 239) 80 (60, 278) 
Fibrinogen (mg/dL) 2008.5 (1783, 2305) 1966 (1664, 2149) 1913 (1647, 
2260) 
Data are median value (interquartile range) or number (%) of patients. 
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Abbreviations: AZT, zidovudine; D4T, stavudine; ABC, abacavir; BMI, body mass index; 
HOMA-IR, homeostatic model assessment of insulin resistance; sTNFR1 and 2, soluble tumor 
necrosis factor alpha receptor 1 and 2;  sCD14, soluble CD14; sCD163, soluble CD163. 
a 
p<0.05 for between group differences 
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Table 2: Absolute Change between Week 0 and 48 in HOMA-IR and Inflammatory Biomarkers 
 
 AZT arm 
N=35 
P 
values
a
 
D4T arm 
N=42 
P 
values
a
 
ABC arm 
N=41 
P 
values
a
 
HOMA-IR 0.04 (-0.15, 
0.32) 
0.65 -0.01 (-0.15, 
0.3) 
0.56 0.03 (-0.25, 
0.59) 
0.69 
sTNFR1 (pg/mL) -189.5 (-413.5, -
93.5) 
0.003 -176.5 (-469, 
-44) 
0.002 -223 (-499, -
32) 
<0.001 
sTNFR2 (pg/mL) -2190 (-3762, -
1409) 
<0.001 -2335 (-4203, 
-1228) 
<0.001 -2067 (-4358, 
-1139) 
<0.001 
sCD14 (ng/mL) 61 (-328.5, 
368.3)
b
 
0.75 -8 (-280, 
490.5)
 b
 
0.29 284.5 (-17.5, 
638.5)
 b
 
<0.001 
sCD163 (ng/mL) -490 (-665.5, -
260.5) 
<0.001 -378 (-553.7, 
-20) 
<0.001 -372.7 (-
720.5, -103.5) 
<0.001 
Oxidized LDL 
(u/L) 
-18.5 (-109.5, 
18) 
0.51 -26 (-98, 54) 0.18 -6 (-154, 113) 0.24 
Fibrinogen 
(mg/dL) 
-171 (-553.5, 
408.5) 
0.20 -82 (-553, 
227) 
0.65 -75 (-290, 
300) 
0.96 
Data are median value (interquartile range).  
 
a 
For within group differences.
b
 p<0.05 for between group differences. 
Abbreviations: AZT, zidovudine; D4T, stavudine; ABC, abacavir; HOMA-IR, homeostatic 
model assessment of insulin resistance; sTNFR1 and 2, soluble tumor necrosis factor alpha 
receptor 1 and 2; sCD14, soluble CD14; sCD163, soluble CD163. 
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Table 3: Factors univariately associated with HOMA-IR and inflammatory markers at baseline 
 ρ = Spearman correlation coefficient 
Abbreviations: HOMA-IR, homeostatic model assessment of insulin resistance; sTNFR1 and 2, 
soluble tumor necrosis factor alpha receptor 1 and 2; Ox-LDL, oxidized LDL; sCD14, soluble 
CD14; sCD163, soluble CD163; LDL, low density lipoproteins. 
Ox- LDL: oxidized LDL 
 
  
 sTNFR1 sTNFR2 sCD14 sCD163 Ox-LDL fibrinogen 
 ρ P 
value 
ρ P 
value 
ρ P 
value 
ρ P 
value 
ρ P 
value 
ρ P value 
HOMA-IR -0.02 0.82 -0.03 
 
0.73 -0.04 
 
0.64 -
0.03 
 
0.72 0.2 
 
0.04 - 0.02 
 
0.87 
Age (years) -0.62 <0.001 -0.66 <0.001 -0.17 0.07 -
0.11 
0.23 -
0.22 
0.02 0.05 0.60 
Weight-for-
age Z score 
-0.55 <0.001 -0.49 <0.001 -0.35 <0.001 -
0.15 
0.10 -
0.22 
0.02 0.05 0.60 
Weight 
(kg) 
-0.69 
 
<0.001 -0.68 
 
<0.001 -0.29 0.002 -
0.13 
 
0.16 -
0.22 
 
0.02 0.04 
 
0.7 
Cholesterol 
(mg/dL) 
-0.26 
 
0.007 -0.26 
 
0.009 -0.21 
 
0.03 -
0.03 
 
0.72 -
0.02 
 
0.84 0.14 
 
0.15 
LDL 
(mg/dL) 
-0.38 <0.001 -0.35 
 
0.003 -0.22 
 
0.02 -
0.11 
 
0.26 -
0.06 
 
0.55 0.15 
 
0.14 
CD4 αbs 
(cells/mm
3
) 
0.29 0.002 0.26 
 
0.004 0.03 
 
0.72 0.06 
 
0.55 0.38 
 
<0.001 -0.08 
 
0.40 
CD4 % -0.1 
 
0.28 -0.09 
 
0.35 -0.22 
 
0.02 -
0.03 
 
0.75 0.27 
 
0.005 -0.07 
 
0.47 
Viral load 
(copies/mL) 
0.248 
 
0.009 0.23 
 
0.01 0.06 
 
0.50 -
0.03 
 
0.76 -
0.01 
 
0.91 -0.08 
 
0.38 
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Table 4:  Factors associated with relative change from baseline to week 48 in HOMA-IR  
 Univariable Analysis Multivariable Analysis 
 Spearman 
Correlation 
P value Parameter 
Estimate 
P value 
Age (years)   0.003 0.969 
Male    -0.375 0.077 
Relative Change in 
BMI (kg/m
2
) 
  0.482 0.649 
Family history of 
diabetes 
  0.585 0.161 
Relative change in 
sTNFR1 
-0.11 0.28   
Relative change in 
sTNFR2 
-0.15 0.13   
Relative change in 
sCD14 
-0.07 0.50   
Relative change in 
sCD163 
0.20 0.04 0.635 0.030 
Abbreviations: HOMA-IR, homeostatic model assessment of insulin resistance; sTNFR1 and 2, 
soluble tumor necrosis factor alpha receptor 1 and 2; BMI, body mass index; sCD14, soluble 
CD14; sCD163, soluble CD163. 
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